Table 3 Correlation analysis results (range over different time points) from Phase III trials with tiotropium Respimat® in patients aged 12–75 years with persistent asthma – all patients evaluated for efficacy
From: Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1
Trial | In-clinic pre-dose FEV1 vs. in-clinic pre-dose PEF | In-clinic pre-dose FEV1 vs. home-measured pre-dose FEV1 | In-clinic pre-dose PEF vs. home-measured pre-dose PEF |
|---|---|---|---|
PCC (range) | ICC (range) | ICC (range) | |
RubaTinA-asthma®a | 0.826–0.831 | 0.558–0.601 | 0.683–0.794 |
PensieTinA-asthma®b | 0.821–0.838 | 0.634–0.691 | 0.718–0.724 |
GraziaTinA-asthma®c | 0.822–0.835 | 0.818–0.840 | 0.834–0.841 |
MezzoTinA-asthma®d | 0.837–0.852 | 0.758–0.776 | 0.833–0.846 |
CadenTinA-asthma®e | 0.773–0.791 | 0.741–0.769 | 0.780–0.825 |
PrimoTinA-asthma®f | In-clinic pre-dose PEF was not assessed | 0.778–0.792 | In-clinic pre-dose PEF was not assessed |